The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
The category of IFG was introduced in the late 1990s to denote a state of non-diabetic hyperglycaemia defined by a fasting plasma glucose (FPG) concentration between 6.1 and 6.9 mmol/l. In 2003 the American Diabetes Association recommended that this diagnostic threshold be lowered to 5.6 mmol/l. The justification for lowering the threshold has been questioned. This simple change in cut-off value creates a pandemic of IFG, with a two- to five-fold increase in the prevalence of IFG across the world. Such a change in threshold has far-reaching public health implications. The European Diabetes Epidemiology Group (EDEG) has reviewed the evidence for this lower cut-off point for the definition of IFG and concludes that the previous definition should not be altered. EDEG further recommends that the value of all categorical definitions of non-diabetic hyperglycaemia should be reconsidered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“diabetes in people with IGT [20–23].”
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“diabetes in people with IGT [20–23].”
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784 · cited 1×
“For example, we do not yet know the total benefit or the total cost to an individual who is designated at risk for diabetes by either test, by any criterion’ [1].”
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543 · cited 1×
“diabetes in people with IGT [20–23].”
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624 · cited 12×
“The relationship between levels of fasting glucose and future risk of diabetes A considerable amount of attention in the literature has been paid to comparisons between IFG and IGT and the relative merits of one compared with the other in predicting future diabetes [2, 3].”
InfluentialLevitan, E. B., Song, Y., Ford, E. S., & Liu, S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2147 · Cited by 668 · cited 1×
“However, the association with fasting glucose was non-linear, with a possible threshold effect at around 5.6 mmol/l [ 12 ].”
Influential[The Da Qing IGT and Diabetes study].
Ayame, H. (2005) · PubMed · Cited by 658
de Vegt, F., Dekker, J. M., Ruhé, H. G., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (1999) · Diabetologia · doi:10.1007/s001250051249 · Cited by 613 · cited 1×
“Nearly identical findings were reported from the Dutch Hoorn study, in which the age- and sex-adjusted RR for CVD mortality was 1.43 (0.79–2.60) in the FPG group 6.1– 6.9 mmol/l, but 0.63 (0.34–1.19) in the new IFG group of 5.6–6.0 mmol/l [ 14 ].”
InfluentialSelf-citationThe Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572 · cited 1×
“In contrast, a recent report of the US Diabetes Prevention Program (DPP) did not replicate this finding for metformin, but there was a risk reduction in hypertension with intensive lifestyle intervention [25].”
Gabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1108 · Cited by 568
Lowering the Criterion for Impaired Fasting Glucose Is in Order
Genuth, S. (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3331 · Cited by 559
The DECODE Study Group, & on behalf of the European Diabetes Epidemiology Group (2003) · Diabetes Care · doi:10.2337/diacare.26.3.688 · Cited by 516
Normal fasting plasma glucose levels and type 2 diabetes in young men
Tirosh, A., Shai, I., Tekes-Manova, D., Israeli, E., Pereg, D., Shochat, T., Kochba, I., & Rudich, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050080 · Cited by 508 · cited 1×
“Indeed, recent evidence suggests that higher fasting glucose levels within the normoglycaemic range constitute an independent risk factor for type 2 diabetes among young men [8].”
Shaw, J. E., Zimmet, P. Z., de Courten, M., Dowse, G. K., Chitson, P., Gareeboo, H., Hemraj, F., Fareed, D., Tuomilehto, J., & Alberti, K. G. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.399 · Cited by 329 · cited 1×
“A considerable amount of attention in the literature has been paid to comparisons between IFG and IGT and the relative merits of one compared with the other in predicting future diabetes [2, 3 ]. However, in the context of considering the threshold for defining IFG, these comparison arguments are less clinically relev…”
Blood glucose and risk of cardiovascular disease in the Asia Pacific region.
Asia Pacific Cohort Studies Collaboration (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2836 · Cited by 302 · cited 1×
“9 mmol/l, without a threshold effect [11].”
The Relation of Fasting and 2-h Postchallenge Plasma Glucose Concentrations to Mortality
Sorkin, J. D., Muller, D. C., Fleg, J. L., & Andres, R. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2626 · Cited by 189 · cited 3×
“The findings were replicated for total mortality in the Baltimore Longitudinal Study of Aging [13].”
Fasting proinsulin concentrations predict the development of type 2 diabetes.
Wareham, N. J., Byrne, C. D., Williams, R., Day, N. E., & Hales, C. N. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.262 · Cited by 173 · cited 1×
“UK [33] Population-based cohort study”
Self-citationBlake, D. R., Meigs, J. B., Muller, D. C., Najjar, S. S., Andres, R., & Nathan, D. M. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2095 · Cited by 169 · cited 4×
“The findings were replicated for total mortality in the Baltimore Longitudinal Study of Aging [13].”
InfluentialImpaired fasting glucose or impaired glucose tolerance
Shaw, J. E., Zimmet, P., de Courten, M., Gk, D., Chitson, P., Gareeboo, H., Hemraj, F., Fareed, D., Tuomilehto, J., & Kgmm., A. (1999) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) · Cited by 169
Borch‐Johnsen, K., Colagiuri, S., Balkau, B., Gl�mer, C., Carstensen, B., Ramachandran, A., Dong, Y., & Gao, W. (2004) · Diabetologia · doi:10.1007/s00125-004-1468-6 · Cited by 154 · cited 1×
“The lowered threshold would increase the prevalence of IFG from 11.8 to 37.6% in Denmark, from 15.9 to 45.2% in France, from 11.2 to 26.7% in urban China, from 10.6 to 37.6% in urban India, from 9.5 to 28.5% in the USA [ 29 ] and from 9.5 to 32.3% in Singapore [30].”
InfluentialSelf-citationImpaired fasting glucose: how low should it go?
Shaw, J. E., Zimmet, P. Z., Hodge, A. M., de Courten, M., Dowse, G. K., Chitson, P., Tuomilehto, J., & Alberti, K. G. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.34 · Cited by 146 · cited 1×
“So, what do we know about the shape of the risk curve relating fasting glucose to new-onset diabetes? In a study of 4,721 nondiabetic individuals with a repeat OGTT at 5 years of follow-up, the risk of incident diabetes increased with increasing baseline fasting glucose, but there was little evidence of a threshold ef…”
InfluentialHanefeld, M., Koehler, C., Henkel, E., Fuecker, K., Schaper, F., & Temelkova‐Kurktschiev, T. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00408.x · Cited by 118
Increased Mortality Risks of Pre-Diabetes (Impaired Fasting Glucose) in Taiwan
Wen, C. P., Cheng, T. Y. D., Tsai, S. P., Hsu, H. L., & Wang, S. L. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2756 · Cited by 105 · cited 2×
“definition comes from a Taiwanese study [10].”
Lowering the Criterion for Impaired Fasting Glucose
Tai, E. S., Goh, S. Y., Lee, J. J. M., Wong, M.-S., Heng, D., Hughes, K., Chew, S. K., Cutter, J., Chew, W., Gu, K., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1728 · Cited by 92 · cited 1×
“study [30] 8-year follow-up of 915 adults”
Impaired fasting glucose is not a risk factor for atherosclerosis
Hanefeld, M., Temelkova‐Kurktschiev, T., Schaper, F., Henkel, E., Siegert, G., & Koehler, C. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00072.x · Cited by 86 · cited 11×
“The relationship between levels of fasting glucose and future risk of diabetes A considerable amount of attention in the literature has been paid to comparisons between IFG and IGT and the relative merits of one compared with the other in predicting future diabetes [2, 3].”
InfluentialLowering the Criterion for Impaired Fasting Glucose Will Not Provide Clinical Benefit
Davidson, M. B., Landsman, P. B., & Alexander, C. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3329 · Cited by 84 · cited 1×
“There might be potential harm in labelling people; for example, life or medical insurance premiums could potentially increase and IFG could be considered as a pre-existing condition, and thus costs incurred for subsequent diabetes may not be paid [28].”
Qiao, Q., Lindström, J., Valle, T. T., & Tuomilehto, J. O. (2003) · Diabetic Medicine · doi:10.1111/j.1464-5491.2003.01054.x · Cited by 76 · cited 1×
“study [31] Population-based cohort aged”
Self-citationKanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Bittner, V., Cauley, J. A., Hulley, S., & Barrett-Connor, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-10-200505170-00006 · Cited by 73 · cited 5×
“Although there are few studies relating non-diabetic hyperglycaemic categories to CVD outcomes, IGT, but not IFG, has consistently been associated with CHD risk factors.”
InfluentialDyson, P. A., Hammersley, M. S., Morris, R. J., Holman, R. R., & Turner, R. C. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90318-8 · Cited by 73 · cited 1×
“Reinforced healthy lifestyle advice did not achieve sustained lifestyle changes, as measured by body weight and did not result in reduction in glycaemia at the 1year follow-up when compared with a programme of basic healthy lifestyle advice [26].”
Changing the Definition of Impaired Fasting Glucose
Vaccaro, O., & Riccardi, G. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1786 · Cited by 45 · cited 2×
“9 mmol/l) definition of IFG was used [18, 19].”
Wang, J., Yuan, S.-Y., Zhu, L., Fu, H.-J., Li, H., Hu, G., & Tuomilehto, J. O. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.03.002 · Cited by 42
Karunakara, S., Hammersley, M. S., Morris, R. J., Turner, R. C., & Holman, R. R. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90319-x · Cited by 33 · cited 1×
“Sulfonylurea therapy improved glycaemic control and beta cell function at 1 year, but progression to diabetes was not measured [27].”
Cicero, A. F. G., Dormi, A., Nascetti, S., Panourgia, M. P., Grandi, E., D’Addato, S., & Gaddi, A. V. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01485.x · Cited by 28 · cited 1×
“future diabetes [5].”
Balkau, B., Hillier, T. A., Vierron, E., D’Hour, A., L�pinay, P., Royer, B., & Born, C. (2005) · Diabetologia · doi:10.1007/s00125-005-1695-5 · Cited by 17
Self-citationde Vegt, F., Dekker, J. M., Jager, A., Hienkens, E., Kostense, P. J., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (2001) · JAMA · doi:10.1001/jama.285.16.2109 · Cited by 10 · cited 1×
“A considerable amount of attention in the literature has been paid to comparisons between IFG and IGT and the relative merits of one compared with the other in predicting future diabetes [2, 3].”
Self-citation
Cited by
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.161596 · Cited by 1,360
“This change has been contentious and has not been accepted by all organizations (19,38).”
Huang, Y., Cai, X., Mai, W., Li, M., & Hu, Y. (2016) · BMJ · doi:10.1136/bmj.i5953 · Cited by 1,012
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
“profile [6,52,138].”
BackgroundSelf-citationDefinition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome
Punthakee, Z., Goldenberg, R., & Katz, P. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.003 · Cited by 877
“Prediabetes (defined as a state which places individuals at high risk of developing diabetes and its complications) is diagnosed by any of the following criteria: a. IFG (FPG 6.1–6.9 mmol/L) [Grade A, Level 1 (45)] b. IGT (2hPG in a 75 g OGTT 7.8–11.0 mmol/L) [Grade A, Level 1 (45)] c. A1C 6.0%–6.4% (for use in adults…”
BackgroundInfluentialSacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Diabetes Care · doi:10.2337/dc11-9998 · Cited by 718
“This change has been contentious and has not been accepted by all organizations (19,38).”
Metadata
- Authors
- On behalf of, E. D. E. G., Forouhi, N. G., Balkau, B., Borch-Johnsen, K., Dekker, J., Glumer, C., Qiao, Q., Spijkerman, A., Stolk, R., Tabac, A., & Wareham, N. J.
- Affiliations
- MRC Elsie Widdowson Laboratory (GB)
- Inserm (FR)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- University of Helsinki (FI)
- University Medical Center Groningen (NL)
- Corresponding author
- Wareham, N. J.
- Venue
- Diabetologia
- Published
- 2006-03-09
- Volume
- 49
- Issue
- 5
- Pages
- 822-827
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2126463294
- Semantic Scholar
- 24e9ce6a16ed005b7b6ec639d9a58ee46b82770e
- Cited by
- 140
- References
- 36
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 2 · 2023: 7 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 7 · 2018: 5 · 2017: 4 · 2016: 6 · 2015: 12 · 2014: 3 · 2013: 11 · 2012: 5
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- impaired fasting glucose, diagnostic thresholds, cut-off values, non-diabetic hyperglycaemia, fasting blood glucose, American Diabetes Association criteria, diagnostic criteria
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Diabetic Angiopathies, Europe, Fasting, Humans, Prevalence, Glucose Intolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.